Skip to main content
SpringerLink
Log in

Advances, Promises, and Challenges in HIV Prevention

  • Chapter
  • First Online:
Biomedical Advances in HIV Prevention

Abstract

As there are over two million new HIV infections each year, there is a critical need for effective HIV prevention strategies. Over the past 3 decades, studies have tested the efficacy of numerous biomedical prevention interventions that have been developed to complement existing behavioral strategies. Until recently, few of these interventions were sufficiently efficacious to merit broad implementation. However, over the past several years, groundbreaking studies have demonstrated the efficacy of several primary and secondary biomedical interventions, which has revitalized the field of HIV prevention. These promising interventions include the administration of antiretroviral medications to high-risk HIV-uninfected persons, known as preexposure prophylaxis, and the early administration of antiretroviral treatment to HIV-infected persons to reduce their infectiousness, a strategy referred to as “Treatment as Prevention.” Voluntary medical male circumcision represents an additional prevention intervention that has been demonstrated to be efficacious and is undergoing scale-up in several regions with generalized HIV epidemics. However, each of these promising interventions faces barriers to achieving optimal effectiveness, such as substantial adherence challenges resulting in conflicting efficacy results for preexposure prophylaxis, structural challenges with scaling-up antiretroviral therapy for Treatment as Prevention, and cultural challenges in increasing male circumcision uptake in communities where the practice has not been normative. If these challenges can be overcome through scientific creativity, perseverance, and political will, a combination of promising biomedical and behavioral interventions could help curb the HIV epidemic.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 129.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 169.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 169.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. UNAIDS Report on the Global AIDS Epidemic 2010. Joint United Nations Programme on HIV/AIDS (UNAIDS). http://www.unaids.org/GlobalReport/default.htm. Accessed 1 June 2012.

  2. Prejean J, Song R, Hernandez A, Ziebell R, Green T, Walker F, et al. Estimated HIV Incidence in the United States, 2006–2009. PLoS One. 2011;6(8):e17502.

    Article  PubMed  CAS  Google Scholar 

  3. Dieffenbach CW, Fauci AS. Thirty years of HIV and AIDS: future challenges and opportunities. Ann Intern Med. 2011;154(11):766–71.

    Article  PubMed  Google Scholar 

  4. Karim SS, Karim QA. Antiretroviral prophylaxis: a defining moment in HIV control. Lancet. 2011;378(9809):e23–5.

    Article  PubMed  Google Scholar 

  5. Cohen MS, Chen YQ, McCauley M, Gamble T, Hosseinipour MC, Kumarasamy N, et al. Prevention of HIV-1 infection with early antiretroviral therapy. N Engl J Med. 2011;365(6):493–505.

    Article  PubMed  CAS  Google Scholar 

  6. Baeten JM, Donnell D, Ndase P, Mugo NR, Campbell JD, Wangisi J, et al. Antiretroviral prophylaxis for HIV prevention in heterosexual men and women. N Engl J Med. 2012;367(5):399–410.

    Article  PubMed  CAS  Google Scholar 

  7. Thigpen MC, Kebaabetswe PM, Paxton LA, Smith DK, Rose CE, Segolodi TM, et al. Antiretroviral preexposure prophylaxis for heterosexual HIV transmission in Botswana. N Engl J Med. 2012;367(5):423–34.

    Article  PubMed  CAS  Google Scholar 

  8. Grant RM, Lama JR, Anderson PL, McMahan V, Liu AY, Vargas L, et al. Preexposure chemoprophylaxis for HIV prevention in men who have sex with men. N Engl J Med. 2010;363(27):2587–99.

    Article  PubMed  CAS  Google Scholar 

  9. Abdool Karim Q, Abdool Karim SS, Frohlich JA, Grobler AC, Baxter C, Mansoor LE, et al. Effectiveness and safety of tenofovir gel, an antiretroviral microbicide, for the prevention of HIV infection in women. Science. 2010;329(5996):1168–74.

    Article  PubMed  CAS  Google Scholar 

  10. Siegfried N, Muller M, Deeks JJ, Volmink J. Male circumcision for prevention of heterosexual acquisition of HIV in men. Cochrane Database Syst Rev 2009(2):CD003362.

    Google Scholar 

  11. Auvert B, Taljaard D, Lagarde E, Sobngwi-Tambekou J, Sitta R, Puren A. Randomized controlled intervention trial of male circumcision for reduction of HIV infection risk: the ANRS 1265 Trial. PLoS Med. 2005;2(11):e298.

    Article  PubMed  Google Scholar 

  12. Montgomery CM, Pool R. Critically engaging: integrating the social and the biomedical in international microbicides research. J Int AIDS Soc. 2011;14(Suppl 2):S4.

    Article  PubMed  Google Scholar 

  13. Kurth AE, Celum C, Baeten JM, Vermund SH, Wasserheit JN. Combination HIV prevention: significance, challenges, and opportunities. Curr HIV/AIDS Rep. 2010;8(1):62–72.

    Article  Google Scholar 

  14. Connor EM, Sperling RS, Gelber R, Kiselev P, Scott G, O’Sullivan MJ, et al. Reduction of maternal-infant transmission of human immunodeficiency virus type 1 with zidovudine treatment. Pediatric AIDS Clinical Trials Group Protocol 076 Study Group. N Engl J Med. 1994;331(18):1173–80.

    Article  PubMed  CAS  Google Scholar 

  15. Obiero J, Mwethera PG, Hussey GD, Wiysonge CS. Vaginal microbicides for reducing the risk of sexual acquisition of HIV infection in women: systematic review and meta-analysis. BMC Infect Dis. 2012;12(1):289.

    Article  PubMed  Google Scholar 

  16. Van Damme L, Corneli A, Ahmed K, Agot K, Lombaard J, Kapiga S, et al. Preexposure prophylaxis for HIV infection among African women. N Engl J Med. 2012;367(5):411–22.

    Article  PubMed  CAS  Google Scholar 

  17. Marrazzo JM, Ramjee G, Nair GB, Palanee T, Mkhiza B, Nakabiito C et al Pre-exposure Prophylaxis for HIV in Women: Daily Oral Tenofovir, Oral Tenofovir/Emtricitabine, or Vaginal Tenofovir Gel in the VOICE Study (MTN 003). Conference on Retroviruses and Opportunistic Infections. Atlanta; 3–6 March 2013. http://www.retroconference.org/2013b/Abstracts/47951.htm. Accessed 12 April 2013.

  18. Polsky B, Baron PA, Gold JW, Smith JL, Jensen RH, Armstrong D. In vitro inactivation of HIV-1 by contraceptive sponge containing nonoxynol-9. Lancet. 1988;1(8600):1456.

    Article  PubMed  CAS  Google Scholar 

  19. Kreiss J, Ngugi E, Holmes K, Ndinya-Achola J, Waiyaki P, Roberts PL, et al. Efficacy of nonoxynol 9 contraceptive sponge use in preventing heterosexual acquisition of HIV in Nairobi prostitutes. J Am Med Assoc. 1992;268(4):477–82.

    Article  CAS  Google Scholar 

  20. Roddy RE, Zekeng L, Ryan KA, Tamoufe U, Weir SS, Wong EL. A controlled trial of nonoxynol 9 film to reduce male-to-female transmission of sexually transmitted diseases. N Engl J Med. 1998;339(8):504–10.

    Article  PubMed  CAS  Google Scholar 

  21. Van Damme L, Ramjee G, Alary M, Vuylsteke B, Chandeying V, Rees H, et al. Effectiveness of COL-1492, a nonoxynol-9 vaginal gel, on HIV-1 transmission in female sex workers: a randomised controlled trial. Lancet. 2002;360(9338):971–7.

    Article  PubMed  CAS  Google Scholar 

  22. Pirrone V, Wigdahl B, Krebs FC. The rise and fall of polyanionic inhibitors of the human immunodeficiency virus type 1. Antiviral Res. 2011;90(3):168–82.

    Article  PubMed  CAS  Google Scholar 

  23. Abdool Karim SS, Richardson BA, Ramjee G, Hoffman IF, Chirenje ZM, Taha T, et al. Safety and effectiveness of BufferGel and 0.5 % PRO2000 gel for the prevention of HIV infection in women. AIDS. 2011;25(7):957–66.

    Article  PubMed  CAS  Google Scholar 

  24. McCormack S, Ramjee G, Kamali A, Rees H, Crook AM, Gafos M, et al. PRO2000 vaginal gel for prevention of HIV-1 infection (Microbicides Development Programme 301): a phase 3, randomised, double-blind, parallel-group trial. Lancet. 2010;376(9749):1329–37.

    Article  PubMed  CAS  Google Scholar 

  25. Van Damme L, Govinden R, Mirembe FM, Guedou F, Solomon S, Becker ML, et al. Lack of effectiveness of cellulose sulfate gel for the prevention of vaginal HIV transmission. N Engl J Med. 2008;359(5):463–72.

    Article  PubMed  CAS  Google Scholar 

  26. Meeting Report: Next Steps with 1 % Tenofovir Gel. World Health Organization and Joint United National Programme on HIV/AIDS. 13 January 2011. http://www.who.int/reproductivehealth/topics/rtis/WHO_UNAIDS_Next_steps_tenofovir_gel_Ex_sum.pdf. Accessed 13 December 2011.

  27. Hendrix CW. The clinical pharmacology of antiretrovirals for HIV prevention. Curr Opin HIV AIDS. 2012;7(6):498–504.

    Article  PubMed  CAS  Google Scholar 

  28. Press Release: MTN Statement on Decision to Discontinue Use of Tenofovir Gel in VOICE, a Major HIV Prevention Study in Women. Microbicides Trial Network. 28 November 2011. http://www.mtnstopshiv.org/node/3909. Accessed 1 June 2012.

  29. Mayer KH, Venkatesh KK. Interactions of HIV, other sexually transmitted diseases, and genital tract inflammation facilitating local pathogen transmission and acquisition. Am J Reprod Immunol. 2011;65(3):308–16.

    Article  PubMed  Google Scholar 

  30. Follow-on African Consortium for Tenofovir Studies (FACTS) [website]. http://www.facts-consortium.co.za/?page_id=83. Accessed 1 June 2012.

  31. National Antenatal Sentinal HIV and Syphilis Prevalence Survey in South Africa, 2010. National Department of Health, South Africa. http://www.doh.gov.za/docs/reports/2011/hiv_aids_survey.pdf. Accessed 13 Dec 2011.

  32. Beyrer C. Global prevention of HIV infection for neglected populations: men who have sex with men. Clin Infect Dis. 2010;50(Suppl 3):S108–13.

    Article  Google Scholar 

  33. Baral S, Sifakis F, Cleghorn F, Beyrer C. Elevated risk for HIV infection among men who have sex with men in low- and middle-income countries 2000–2006: a systematic review. PLoS Med. 2007;4(12):e339.

    Article  PubMed  Google Scholar 

  34. Beyrer C, Baral SD, Griensven F van, Goodreau SM, Chariyalertsak S, Wirtz AL, et al. Global epidemiology of HIV infection in men who have sex with men. Lancet. 2012;380(9839):367–77.

    Article  PubMed  Google Scholar 

  35. Cranage M, Sharpe S, Herrera C, Cope A, Dennis M, Berry N, et al. Prevention of SIV rectal transmission and priming of T cell responses in macaques after local pre-exposure application of tenofovir gel. PLoS Med. 2008;5(8):e157.

    Article  PubMed  CAS  Google Scholar 

  36. Anton PA, Cranston RD, Kashuba A, Hendrix CW, Bumpus NN, Richardson-Harman N, et al. RMP-02/MTN-006: a phase 1 rectal safety, acceptability, pharmacokinetic, and pharmacodynamic study of tenofovir 1 % gel compared with oral tenofovir disoproxil fumarate. AIDS Res Hum Retroviruses. 2012;28(11):1412–21.

    Article  PubMed  CAS  Google Scholar 

  37. Dezzutti CS, Rohan LC, Wang L, Uranker K, Shetler C, Cost M, et al. Reformulated tenofovir gel for use as a dual compartment microbicide. J Antimicrob Chemother. 2012;67(9):2139–42.

    Article  PubMed  CAS  Google Scholar 

  38. McGowan I. Rectal microbicide development. Curr Opin HIV AIDS. 2012;7(6):526–33.

    Article  PubMed  Google Scholar 

  39. Johnson TJ, Clark MR, Albright TH, Nebeker JS, Tuitupou AL, Clark JT, et al. A 90-day tenofovir reservoir intravaginal ring for mucosal HIV prophylaxis. Antimicrob Agents Chemother. 2012;56(12):6272–83.

    Article  PubMed  CAS  Google Scholar 

  40. Romano J, Variano B, Coplan P, Van Roey J, Douville K, Rosenberg Z, et al. Safety and availability of dapivirine (TMC120) delivered from an intravaginal ring. AIDS Res Hum Retroviruses. 2009;25(5):483–8.

    Article  PubMed  CAS  Google Scholar 

  41. Singer R, Mawson P, Derby N, Rodriguez A, Kizima L, Menon R, et al. An intravaginal ring that releases the NNRTI MIV-150 reduces SHIV transmission in macaques. Sci Transl Med. 2012;4(150):150ra123.

    Article  PubMed  CAS  Google Scholar 

  42. Kobayashi K, Seki T, Kawasuji T, Taishi T, Sato A, Fujiwara T et al Antiviral Characteristics Of S/GSK1265744, An HIV Integrase Inhibitor (INI) dosed by oral or long-acting parenteral injection. 52nd Interscience Conference on antimicrobial agents and chemotherapy. San Francisco; Sept 9–12, 2012. http://conference-cast.com/ICAAC/Common/presentation.aspx?ConfId=6&TrackId=11&SessionId=845. Accessed 31 Jan 2012.

  43. Panlilio AL, Cardo DM, Grohskopf LA, Heneine W, Ross CS. Updated U.S. Public Health Service guidelines for the management of occupational exposures to HIV and recommendations for postexposure prophylaxis. MMWR Recomm Rep. 2005;54(RR-9):1–17.

    PubMed  Google Scholar 

  44. Garcia-Lerma JG, Heneine W. Animal models of antiretroviral prophylaxis for HIV prevention. Curr Opin HIV AIDS. 2012;7(6):505–13.

    Article  PubMed  Google Scholar 

  45. García-Lerma J, Otten R, Qari S, Jackson E, Cong M, Masciotra S, et al. Prevention of rectal SHIV transmission in macaques by daily or intermittent prophylaxis with emtricitabine and tenofovir. PLoS Med. 2008;5(2):e28.

    Article  PubMed  CAS  Google Scholar 

  46. Garcia-Lerma JG, Cong ME, Mitchell J, Youngpairoj AS, Zheng Q, Masciotra S, et al. Intermittent prophylaxis with oral truvada protects macaques from rectal SHIV infection. Sci Transl Med. 2010;2(14):14ra4.

    Article  PubMed  CAS  Google Scholar 

  47. Kwara A, DeLong A, Rezk N, Hogan J, Burtwell H, Chapman S, et al. Antiretroviral drug concentrations and HIV RNA in the genital tract of HIV-infected women receiving long-term highly active antiretroviral therapy. Clin Infect Dis. 2008;46(5):719–25.

    Article  PubMed  CAS  Google Scholar 

  48. Hamers RL, Sigaloff KC, Wensing AM, Wallis CL, Kityo C, Siwale M, et al. Patterns of HIV-1 drug resistance after first-line antiretroviral therapy (ART) failure in 6 sub-Saharan African countries: implications for second-line ART strategies. Clin Infect Dis. 2012;54(11):1660–9.

    Article  PubMed  CAS  Google Scholar 

  49. Peterson L, Taylor D, Roddy R, Belai G, Phillips P, Nanda K, et al. Tenofovir disoproxil fumarate for prevention of HIV infection in women: a phase 2, double-blind, randomized, placebo-controlled trial. PLoS Clin Trials. 2007;2(5):e27.

    Article  PubMed  CAS  Google Scholar 

  50. Liu AY, Vittinghoff E, Sellmeyer DE, Irvin R, Mulligan K, Mayer K, et al. Bone mineral density in HIV-negative men participating in a Tenofovir pre-exposure prophylaxis randomized clinical trial in San Francisco. PLoS One. 2011;6(8):e23688.

    Article  PubMed  CAS  Google Scholar 

  51. Cardo DM, Culver DH, Ciesielski CA, Srivastava PU, Marcus R, Abiteboul D, et al. A Case-control study of HIV seroconversion in health care workers after percutaneous exposure. N Engl J Med. 1997;337(21):1485–90.

    Article  PubMed  CAS  Google Scholar 

  52. Mayer KH, Mimiaga MJ, Cohen D, Grasso C, Bill R, Van Derwarker R, et al. Tenofovir DF plus lamivudine or emtricitabine for nonoccupational postexposure prophylaxis (NPEP) in a Boston Community Health Center. J Acquir Immune Defic Syndr. 2008;47(4):494–9.

    Article  PubMed  CAS  Google Scholar 

  53. Roland ME, Neilands TB, Krone MR, Katz MH, Franses K, Grant RM, et al. Seroconversion following nonoccupational postexposure prophylaxis against HIV. Clin Infect Dis. 2005;41(10):1507–13.

    Article  PubMed  Google Scholar 

  54. Mayer KH, Mimiaga MJ, Gelman M, Grasso C. Raltegravir, tenofovir DF, and emtricitabine for postexposure prophylaxis to prevent the sexual transmission of HIV: safety, tolerability, and adherence. J Acquir Immune Defic Syndr. 2012;59(4):354–9.

    Article  PubMed  CAS  Google Scholar 

  55. Schechter M, do Lago RF, Mendelsohn AB, Moreira RI, Moulton LH, Harrison LH. Behavioral impact, acceptability, and HIV incidence among homosexual men with access to postexposure chemoprophylaxis for HIV. J Acquir Immune Defic Syndr. 2004;35(5):519–25.

    Article  PubMed  Google Scholar 

  56. Poynten IM, Jin F, Mao L, Prestage GP, Kippax SC, Kaldor JM, et al. Nonoccupational postexposure prophylaxis, subsequent risk behaviour and HIV incidence in a cohort of Australian homosexual men. AIDS. 2009;23(9):1119–26.

    Article  PubMed  Google Scholar 

  57. Grohskopf L, Gvetadze R, Pathak S, O’Hara B, Mayer K, Liu A, et al. Preliminary analysis of biomedical data from the phase II clinical safety trial of tenofovir disoproxil fumarate (TDF) for HIV-1 pre-exposure prophylaxis (PrEP) among U.S. men who have sex with men (MSM) [Abstract FRLBC102]. XVIII International AIDS Conference. Vienna, Austria; 18–23 July 2010. http://pag.aids2010.org/Abstracts.aspx?AID=17777. Accessed 1 June 2012.

  58. Jacobson DL, Spiegelman D, Knox TK, Wilson IB. Evolution and predictors of change in total bone mineral density over time in HIV-infected men and women in the nutrition for healthy living study. J Acquir Immune Defic Syndr. 2008;49(3):298–308.

    Article  PubMed  CAS  Google Scholar 

  59. Szczech LA. Renal dysfunction and tenofovir toxicity in HIV-infected patients. Top HIV Med. 2008;16(4):122–6.

    PubMed  Google Scholar 

  60. Mulligan K, Glidden DV, Gonzales P, Ramirez-Cardich ME, Liu A, Namwongprom S, et al. Effects of FTC/TDF on bone mineral density in seronegative men from 4 continents: DEXA results of the global iPrEx study [Abstract #94LB]. 18th Conference on retroviruses and opportunistic infections. Boston: 27 February–2 March 2011. http://www.retroconference.org/2011/Abstracts/42550.htm. Accessed 1 June 2012.

  61. Golub SA, Kowalczyk W, Weinberger CL, Parsons JT. Preexposure prophylaxis and predicted condom use among high-risk men who have sex with men. J Acquir Immune Defic Syndr. 2010;54(5):548–55.

    Article  PubMed  Google Scholar 

  62. iPrEx Fact Sheet: Rollover Study and Next Steps. 2010. http://www.iprexnews.com/studyresults/pdfembargo/englishversion/iPrEx%20Fact%20Sheet%20Rollover%20Study%20and%20Next%20Steps%20PE.pdf. Accessed 20 Nov 2012.

  63. Hurt CB, Eron JJ Jr, Cohen MS. Pre-exposure prophylaxis and antiretroviral resistance: HIV prevention at a cost? Clin Infect Dis. 2011;53(12):1265–70.

    Article  PubMed  CAS  Google Scholar 

  64. Liegler T, Abdel-Mohsen M, Atchison R, Mehotra M, Schmidt T, Eden C, et al. Drug resistance and minor drug resistant variants in iPrEx [Abstract #97LB]. 18th Conference on Retroviruses and Opportunistic Infections. Boston: 27 February–2 March 2011. http://www.retroconference.org/2011/Abstracts/42553.htm. Accessed 13 Dec 2011.

  65. Amico KR, Liu A, McMahan V, Anderson P, Lama JR, Guanira J, et al. Adherence indicators and PrEP drug levels in the iPrEx study [Abstract #95LB]. 18th Conference on Retroviruses and Opportunistic Infections. Boston; 27 February-2 March 2011. http://www.retroconference.org/2011/Abstracts/42627.htm. Accesssed on: 1 June 2012.

  66. Guedou FA, Van Damme L, Mirembe F, Solomon S, Becker M, Deese J, et al. Intermediate vaginal flora is associated with HIV prevalence as strongly as bacterial vaginosis in a cross-sectional study of participants screened for a randomised controlled trial. Sex Transm Infect. 2012;88(7):545–51.

    Article  PubMed  Google Scholar 

  67. Muchomba FM, Gearing RE, Simoni JM, El-Bassel N. State of the science of adherence in pre-exposure prophylaxis and microbicide trials. J Acquir Immune Defic Syndr. 2012;61(4):490–8.

    Article  PubMed  CAS  Google Scholar 

  68. Hendrix C, Minnis A, Guddera V, Riddler S, Salata R, Nakabiito C, et al. MTN-001: A phase 2 cross-over study of daily oral and vaginal tfv in healthy, sexually active women results in significantly different product acceptability and vaginal tissue drug concentrations [Abstract #34LB]. 18th Conference on Retroviruses and Opportunistic Infections. Boston; 27 February- 2 March, 2011. http://www.retroconference.org/2011/Abstracts/42418.htm. Accessed 13 Dec 2011.

  69. Minnis AM, Gandham S, Richardson BA, Guddera V, Chen BA, Salata R, et al. Adherence and acceptability in MTN 001: a randomized cross-over trial of daily oral and topical tenofovir for HIV prevention in women. AIDS Behav. 2013;17(2):737–47.

    Article  PubMed  Google Scholar 

  70. AIDS vaccine advocacy coalition [website]. http://avac.org/. Accessed 1 June 2012.

  71. ClincalTrials.gov: pre-exposure prophylaxis in YMSM [website]. http://clinicaltrials.gov/show/NCT01033942. Accessed 23 Nov 2012.

  72. Vernazza PL, Graf I, Sonnenberg-Schwan U, Geit M, Meurer A. Preexposure prophylaxis and timed intercourse for HIV-discordant couples willing to conceive a child. AIDS. 2011;25(16):2005–8.

    Article  PubMed  Google Scholar 

  73. Matthews LT, Crankshaw T, Giddy J, Kaida A, Smit JA, Ware NC, et al. Reproductive decision-making and periconception practices among HIV-positive men and women attending HIV services in Durban, South Africa. AIDS Behav. 2013;17(2):461–70.

    Article  PubMed  Google Scholar 

  74. Matthews LT, Baeten JM, Celum C, Bangsberg DR. Periconception pre-exposure prophylaxis to prevent HIV transmission: benefits, risks, and challenges to implementation. AIDS. 2010;24(13):1975–82.

    Article  PubMed  Google Scholar 

  75. Brown KC, Patterson KB, Malone SA, Shaheen NJ, Prince HM, Dumond JB, et al. Single and multiple dose pharmacokinetics of maraviroc in saliva, semen, and rectal tissue of healthy HIV-negative men. J Infect Dis. 2011;203(10):1484–90.

    Article  PubMed  CAS  Google Scholar 

  76. Abraham BK, Gulick R. Next-generation oral preexposure prophylaxis: beyond tenofovir. Curr Opin HIV AIDS. 2012;7(6):600–6.

    Article  PubMed  Google Scholar 

  77. Dumond JB, Patterson KB, Pecha AL, Werner RE, Andrews E, Damle B, et al. Maraviroc concentrates in the cervicovaginal fluid and vaginal tissue of HIV-negative women. J Acquir Immune Defic Syndr. 2009;51(5):546–53.

    Article  PubMed  Google Scholar 

  78. Mutua G, Sanders E, Mugo P, Anzala O, Haberer JE, Bangsberg D, et al. Safety and adherence to intermittent pre-exposure prophylaxis (PrEP) for HIV-1 in African men who have sex with men and female sex workers. PLoS One. 2012;7(4):e33103.

    Article  PubMed  CAS  Google Scholar 

  79. Van der Elst EM,M, Mugo P, et al. High acceptability of HIV pre-exposure prophylaxis but challenges in adherence and use: qualitative insights from a Phase I trial of intermittent and daily PrEP in at-risk populations in Kenya. AIDS Behav. 2013;17(6):2162–72.

    Article  PubMed  Google Scholar 

  80. RA K, McMahan V, Goicochea P, Vargas L, Marcus JL, Grant RM, et al. Supporting study product use and accuracy in self-report in the iPrEx study: next step counseling and neutral assessment. AIDS Behav. 2012;16(5):1243–59.

    Article  Google Scholar 

  81. Psaros C. Evaluation and process outcomes from an adherence intervention to support HIV pre-exposure prophylaxis (PrEP) adherence in HIV serodiscordant couples in Uganda [Abstract 80031]. 7th International Conference on HIV Treatment and Prevention Adherence. Miami Beach; June 5–7, 2012. http://www.iapac.org/AdherenceConference/presentations/ADH7_80031.pdf. Accessed 31 Jan 2013.

  82. Liu A. Implementing PrEP in the Real World: Key issues and challenges for MSM populations. Presentation at the 6th National Scientific Meeting of the Social and Behavioral Sciences Research Network. http://www.cfarsbsrn2012.com/wp-content/uploads/2012/04/Liu-Al.pdf. Accessed 23 Nov 2012.

  83. Amico KR. Adherence to preexposure chemoprophylaxis: the behavioral bridge from efficacy to effectiveness. Curr Opin HIV AIDS. 2012;7(6):542–8.

    Article  PubMed  Google Scholar 

  84. Truvada approved to reduce the risk of sexually transmitted HIV in people who are not infected with the virus. U.S. Food and Drug Administration. 16 July 2012. http://www.fda.gov/ForConsumers/ByAudience/ForPatientAdvocates/HIVandAIDSActivities/ucm312264.htm. Accessed 17 July 2012.

  85. Krakower DS, Mimiaga MJ, Rosenberger JG, Novak DS, Mitty JA, White JM, et al. Limited awareness and low immediate uptake of pre-exposure prophylaxis among men who have sex with men using an internet social networking site. PLoS One. 2012;7(3):e33119.

    Article  PubMed  CAS  Google Scholar 

  86. Eisingerich AB, Wheelock A, Gomez GB, Garnett GP, Dybul MR, Piot PK. Attitudes and acceptance of oral and parenteral HIV preexposure prophylaxis among potential user groups: a multinational study. PLoS One. 2012;7(1):e28238.

    Article  PubMed  CAS  Google Scholar 

  87. Holt M, Murphy DA, Callander D, Ellard J, Rosengarten M, Kippax SC, et al. Willingness to use HIV pre-exposure prophylaxis and the likelihood of decreased condom use are both associated with unprotected anal intercourse and the perceived likelihood of becoming HIV positive among Australian gay and bisexual men. Sex Transm Infect. 2012;88(4):258–63.

    Article  PubMed  Google Scholar 

  88. White JM, Mimiaga MJ, Krakower DS, Mayer KH. Evolution of massachusetts physician attitudes, knowledge, and experience regarding the use of antiretrovirals for HIV prevention. AIDS Patient Care STDS. 2012;26(7):395–405.

    PubMed  Google Scholar 

  89. Maznavi K, Hardy D, Bredeek F. Pre-exposure prophylaxis (PrEP) for HIV: An online survey of HIV healthcare providers evaluating their knowledge, perception, and prescription of PrEP. 49th Annual Meeting of the Infectious Diseases Society of America. Boston, MA; 2011.

    Google Scholar 

  90. SFDPH to Launch PrEP Demonstration Project for HIV Prevention [press release]. 17 September 2012. http://www.sfdph.org/dph/files/newsMediadocs/2012PR/DemoProjectFINAL.pdf. Accessed 23 Nov 2012.

  91. Hayes R, Watson-Jones D, Celum C, Wijgert J van de, Wasserheit J. Treatment of sexually transmitted infections for HIV prevention: end of the road or new beginning? AIDS. 2010;24(Suppl 4):S15–26.

    Article  PubMed  Google Scholar 

  92. Donnell D, Baeten JM, Kiarie J, Thomas KK, Stevens W, Cohen CR, et al. Heterosexual HIV-1 transmission after initiation of antiretroviral therapy: a prospective cohort analysis. The Lancet. 2010;375(9731):2092–8.

    Article  Google Scholar 

  93. Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. Department of Health and Human Services. http://aidsinfo.nih.gov/contentfiles/lvguidelines/adultandadolescentgl.pdf. In: March 27, 2012. p. 1–161. Accessed 24 Nov 2012.

  94. Laga M, Manoka A, Kivuvu M, Malele B, Tuliza M, Nzila N, et al. Non-ulcerative sexually transmitted diseases as risk factors for HIV-1 transmission in women: results from a cohort study. AIDS. 1993;7(1):95–102.

    Article  PubMed  CAS  Google Scholar 

  95. Vincenzi I de. A longitudinal study of human immunodeficiency virus transmission by heterosexual partners. European Study Group on Heterosexual Transmission of HIV. N Engl J Med. 1994;331(6):341–6.

    Article  PubMed  Google Scholar 

  96. Cameron DW, Simonsen JN, D’Costa LJ, Ronald AR, Maitha GM, Gakinya MN, et al. Female to male transmission of human immunodeficiency virus type 1: risk factors for seroconversion in men. Lancet. 1989;2(8660):403–7.

    Article  PubMed  CAS  Google Scholar 

  97. Plummer FA, Simonsen JN, Cameron DW, Ndinya-Achola JO, Kreiss JK, Gakinya MN, et al. Cofactors in male-female sexual transmission of human immunodeficiency virus type 1. J Infect Dis. 1991;163(2):233–9.

    Article  PubMed  CAS  Google Scholar 

  98. Grosskurth H, Mosha F, Todd J, Mwijarubi E, Klokke A, Senkoro K, et al. Impact of improved treatment of sexually transmitted diseases on HIV infection in rural Tanzania: randomised controlled trial. Lancet. 1995;346(8974):530–6.

    Article  PubMed  CAS  Google Scholar 

  99. Gray RH, Wawer MJ, Brookmeyer R, Sewankambo NK, Serwadda D, Wabwire-Mangen F, et al. Probability of HIV-1 transmission per coital act in monogamous, heterosexual, HIV-1-discordant couples in Rakai, Uganda. Lancet. 2001;357(9263):1149–53.

    Article  PubMed  CAS  Google Scholar 

  100. Baeten JM, Strick LB, Lucchetti A, Whittington WL, Sanchez J, Coombs RW, et al. Herpes simplex virus (HSV)-suppressive therapy decreases plasma and genital HIV-1 levels in HSV-2/HIV-1 coinfected women: a randomized, placebo-controlled, cross-over trial. J Infect Dis. 2008;198(12):1804–8.

    Article  PubMed  CAS  Google Scholar 

  101. Zuckerman RA, Lucchetti A, Whittington WL, Sanchez J, Coombs RW, Magaret A, et al. HSV suppression reduces seminal HIV-1 levels in HIV-1/HSV-2 co-infected men who have sex with men. AIDS. 2009;23(4):479–83.

    Article  PubMed  CAS  Google Scholar 

  102. Zuckerman RA, Lucchetti A, Whittington WL, Sanchez J, Coombs RW, Zuniga R, et al. Herpes simplex virus (HSV) suppression with valacyclovir reduces rectal and blood plasma HIV-1 levels in HIV-1/HSV-2-seropositive men: a randomized, double-blind, placebo-controlled crossover trial. J Infect Dis. 2007;196(10):1500–8.

    Article  PubMed  CAS  Google Scholar 

  103. Nagot N, Ouedraogo A, Foulongne V, Konate I, Weiss HA, Vergne L, et al. Reduction of HIV-1 RNA levels with therapy to suppress herpes simplex virus. N Engl J Med. 2007;356(8):790–9.

    Article  PubMed  CAS  Google Scholar 

  104. Celum C, Wald A, Lingappa JR, Magaret AS, Wang RS, Mugo N, et al. Acyclovir and transmission of HIV-1 from persons infected with HIV-1 and HSV-2. N Engl J Med. 2010;362(5):427–39.

    Article  PubMed  CAS  Google Scholar 

  105. Celum C, Wald A, Hughes J, Sanchez J, Reid S, Delany-Moretlwe S, et al. Effect of aciclovir on HIV-1 acquisition in herpes simplex virus 2 seropositive women and men who have sex with men: a randomised, double-blind, placebo-controlled trial. Lancet. 2008;371(9630):2109–19.

    Article  PubMed  CAS  Google Scholar 

  106. Tanton C, Abu-Raddad LJ, Weiss HA. Time to refocus on HSV interventions for HIV prevention? J Infect Dis. 2011;204(12):1822–6.

    Article  PubMed  Google Scholar 

  107. Quinn TC, Wawer MJ, Sewankambo N, Serwadda D, Li C, Wabwire-Mangen F, et al. Viral load and heterosexual transmission of human immunodeficiency virus type 1. Rakai Project Study Group. N Engl J Med. 2000;342(13):921–9.

    Article  PubMed  CAS  Google Scholar 

  108. Eshleman SH, Hudelson SE, Redd AD, Wang L, Debes R, Chen YQ, et al. Analysis of genetic linkage of HIV from couples enrolled in the HIV Prevention Trials Network 052 trial. J Infect Dis. 2011;204(12):1918–26.

    Article  PubMed  CAS  Google Scholar 

  109. Gardner EM, McLees MP, Steiner JF, Del Rio C, Burman WJ. The spectrum of engagement in HIV care and its relevance to test-and-treat strategies for prevention of HIV infection. Clin Infect Dis. 2011;52(6):793–800.

    Article  PubMed  Google Scholar 

  110. Marks G, Gardner LI, Craw J, Giordano TP, Mugavero MJ, Keruly JC, et al. The spectrum of engagement in HIV care: do more than 19 % of HIV-infected persons in the US have undetectable viral load? Clin Infect Dis. 2011;53(11):1168–9. (Author’s reply 1169–70).

    Article  PubMed  Google Scholar 

  111. Forsyth AD, Valdiserri RO. Reaping the prevention benefits of highly active antiretroviral treatment: policy implications of HIV Prevention Trials Network 052. Curr Opin HIV AIDS. 2012;7(2):111–6.

    Article  PubMed  CAS  Google Scholar 

  112. Montaner JS, Lima VD, Barrios R, Yip B, Wood E, Kerr T, et al. Association of highly active antiretroviral therapy coverage, population viral load, and yearly new HIV diagnoses in British Columbia, Canada: a population-based study. Lancet. 2010;376(9740):532–9.

    Article  PubMed  Google Scholar 

  113. Das M, Chu PL, Santos GM, Scheer S, Vittinghoff E, McFarland W, et al. Decreases in community viral load are accompanied by reductions in new HIV infections in San Francisco. PLoS One. 2010;5(6):e11068.

    Article  PubMed  CAS  Google Scholar 

  114. Geng EH, Hare CB, Kahn JO, Jain V, Van Nunnery T, Christopoulos KA, et al. The effect of a “Universal Antiretroviral Therapy” recommendation on HIV RNA levels among HIV-infected patients entering care with a CD4 count greater than 500/muL in a public health setting. Clin Infect Dis. 2012;55(12):1690–7.

    Article  PubMed  CAS  Google Scholar 

  115. Tanser F, Barnighausen T, Graspa E, Newell ML. Effect of ART Coverage on rate of new HIV Infections in a hyper-endemic, rural population: South Africa [#136LB]. 19th Conference on Retroviruses and Opportunistic Infections. Seattle; Mar 5–8, 2012. http://www.retroconference.org/2012b/Abstracts/45379.htm. Accessed 31 Jan 2013.

  116. Floyd S, Marston M, Baisley K, Wringe A, Herbst K, Chihana M, et al. The effect of antiretroviral therapy provision on all-cause, AIDS and non-AIDS mortality at the population level–a comparative analysis of data from four settings in Southern and East Africa. Trop Med Int Health. 2012;17(8):e84–93.

    Article  PubMed  Google Scholar 

  117. Herbst AJ, Cooke GS, Barnighausen T, KanyKany A, Tanser F, Newell ML. Adult mortality and antiretroviral treatment roll-out in rural KwaZulu-Natal, South Africa. Bull World Health Organ. 2009;87(10):754–62.

    Article  PubMed  Google Scholar 

  118. Krakower D, Mitty JA, Trinidad J, Mayer KH. HIV Providers’ Perceived barriers and facilitators to implementing treatment as prevention in clinical practice: a qualitative study [Abstract 101]. Forum for Collaborative HIV Research. Washington, D.C.: 26–28 November 2012.

    Google Scholar 

  119. Myers JE, Braunstein SL, Shepard CW, Cutler BH, Mantsios AR, Sweeney MM, et al. Assessing the impact of a community-wide HIV testing scale-up initiative in a major urban epidemic. J Acquir Immune Defic Syndr. 2012;61(1):23–31.

    Article  PubMed  Google Scholar 

  120. Myers JJ, Bradley-Springer L, Kang Dufour MS, Koester KA, Beane S, Warren N, et al. Supporting the integration of HIV testing into primary care settings. Am J Public Health. 2012;102(6):e25–32.

    Article  PubMed  Google Scholar 

  121. Coates T, Eshleman S, Chariyalertsak S, Chingono A, Gray G, Mbwambo J, et al. 3–6 March 2013. http://www.retroconference.org/2013b/Abstracts/47715.htm. Accessed 12 April 2013. Conference on retroviruses and opportunistic infections. Atlanta.

  122. Taegtmeyer M, MacPherson P, Jones K, Hopkins M, Moorcroft J, Lalloo DG, et al. Programmatic evaluation of a combined antigen and antibody test for rapid HIV diagnosis in a community and sexual health clinic screening programme. PLoS One. 2011;6(11):e28019.

    Article  PubMed  CAS  Google Scholar 

  123. FDA approves first over-the-counter home-use rapid HIV test. 3 July 2012. http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm310542.htm. Accessed 24 Nov 2012.

  124. Paltiel AD, Walensky RP. Home HIV testing: good news but not a game changer. Ann Intern Med. 2012;157(10):744–6.

    Article  PubMed  Google Scholar 

  125. Carballo-Dieguez A, Frasca T, Balan I, Ibitoye M, Dolezal C. Use of a rapid HIV home test prevents HIV exposure in a high risk sample of men who have sex with men. AIDS Behav. 2012;16(7):1753–60.

    Article  PubMed  Google Scholar 

  126. Young MR, Bailey RC, Odoyo-June E, Irwin TE, Obiero W, Ongong’a DO, et al. Safety of over twelve hundred infant male circumcisions using the mogen clamp in Kenya. PLoS One. 2012;7(10):e47395.

    Article  PubMed  CAS  Google Scholar 

  127. Reed JB, Njeuhmeli E, Thomas AG, Bacon MC, Bailey R, Cherutich P, et al. Voluntary medical male circumcision: an HIV prevention priority for PEPFAR. J Acquir Immune Defic Syndr. 2012;60(Suppl 3):S88–95.

    Article  PubMed  Google Scholar 

  128. Rerks-Ngarm S, Pitisuttithum P, Nitayaphan S, Kaewkungwal J, Chiu J, Paris R, et al. Vaccination with ALVAC and AIDSVAX to prevent HIV-1 infection in Thailand. N Engl J Med. 2009;361(23):2209–20.

    Article  PubMed  CAS  Google Scholar 

  129. Rolland M, Gilbert P. Evaluating immune correlates in HIV type 1 vaccine efficacy trials: what RV144 may provide. AIDS Res Hum Retroviruses. 2012;28(4):400–4.

    Article  PubMed  CAS  Google Scholar 

  130. Fauci AS, Folkers GK. Toward an AIDS-free generation. J Am Med Assoc. 2012;308(4):343–4.

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Division of Infectious Diseases, Beth Israel Deaconess Medical Center, 110 Francis St WLMOB Suite GB, Boston, MA, USA

    Douglas Krakower & Kenneth H. Mayer

Authors
  1. Douglas Krakower
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Kenneth H. Mayer
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Douglas Krakower .

Editor information

Editors and Affiliations

  1. Dept. of Human Develop. & Family Studies, University of Connecticut, Storrs, Connecticut, USA

    Lisa A. Eaton

  2. Ctr for Health Intervention & Prevention, University of Connecticut, Storrs, Connecticut, USA

    Seth C. Kalichman

Rights and permissions

Reprints and permissions

Copyright information

© 2014 Springer Science+Business Media New York

About this chapter

Cite this chapter

Krakower, D., Mayer, K. (2014). Advances, Promises, and Challenges in HIV Prevention. In: Eaton, L., Kalichman, S. (eds) Biomedical Advances in HIV Prevention. Springer, New York, NY. https://doi.org/10.1007/978-1-4614-8845-3_1

Download citation

  • DOI: https://doi.org/10.1007/978-1-4614-8845-3_1

  • Published:

  • Publisher Name: Springer, New York, NY

  • Print ISBN: 978-1-4614-8844-6

  • Online ISBN: 978-1-4614-8845-3

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation